Core Viewpoint - AptarGroup, Inc. (ATR) is positioned for growth through its business transformation plan, innovative product launches, and strategic acquisitions [1] Group 1: Business Transformation - The company is focused on business transformation to drive top-line growth, enhance operational excellence, and improve organizational effectiveness [2] - The Beauty segment is undergoing transformation with new capabilities in Asia, cost reduction, and strategies to capitalize on fast-growing application fields [3] Group 2: Segmental Demand - The Pharma segment is experiencing strong demand for proprietary dispensing devices used in various medical applications, with a long-term sales growth target of 7-11% [4] - The Beauty segment is seeing increased sales in prestige and mass fragrances, as well as skin care and color cosmetic solutions, supported by a positive mix of pricing and volume growth [5] Group 3: Strategic Acquisitions - AptarGroup is committed to expanding through acquisitions to enhance technology, geographic presence, and product offerings [5] - In February 2024, Aptar Digital Health acquired Healint to strengthen its digital health portfolio in neurology and signed an agreement with Biogen for digital health solutions [6] - In October 2024, AptarGroup acquired SipNose Nasal Delivery Systems' device technology assets to enhance its intranasal delivery product development [7] Group 4: Innovative Product Launches - The Pharma segment had the highest number of product launches since 2018, with continued momentum expected in 2024 and 2025 [7] - Notable product applications include a nasal delivery system for saline rinse in Germany and an ophthalmic squeeze dispenser in China [8] - In the Beauty segment, various custom dispensing solutions are being utilized by major brands such as L'Oreal and P&G [9] Group 5: Market Performance - ATR shares have increased by 7.8% over the past year, contrasting with a 6.3% decline in the industry [12]

AptarGroup (ATR) Q1 2025 Earnings Call May 02, 2025 09:00 AM ET Company Participants Mary Skafidas - Senior VP of IR & Corporate CommunicationsStephan Tanda - President, CEO & Executive DirectorVanessa Kanu - Executive VP & CFOGeorge Staphos - Managing Director Conference Call Participants Ghansham Panjabi - Senior Research AnalystMatthew Roberts - Equity Research AnalystDaniel Rizzo - AnalystMatt Larew - Research Analyst - HealthcareGabe Hajde - Analyst Operator Ladies and gentlemen, thank you for standing ...

Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $1.2, with a neutralized increase of approximately 5% over the prior year period when accounting for currency effects and tax [4][15] - Reported sales decreased by 3%, with core sales remaining flat compared to the prior year period [14] - Adjusted EBITDA increased by 3% to $183 million, with adjusted diluted earnings per share at $1.2 compared to $1.22 in the prior year [14][15] Business Line Data and Key Metrics Changes - Pharma segment's core sales increased by 3%, with prescription core sales up 10% driven by strong demand for emergency medicines and therapeutics [16] - Consumer Healthcare core sales decreased by 10% due to softer demand for nasal decongestants and cough medicines [16] - Injectables core sales decreased by 8% due to tough comparisons from the prior year, while Active Materials Science solutions saw an 11% increase in core sales [16][18] - Beauty segment's core sales decreased by 3%, with prestige fragrance and facial skincare sales down 11% [19] - Closures segment's core sales decreased by 2%, with product sales growth offset by lower tooling sales [20] Market Data and Key Metrics Changes - The U.S. market showed signs of inventory normalization, while other regions have not yet experienced similar trends [6][37] - The company noted strong demand for GLP-1 and biologics in the injectables market, indicating robust order books [7][36] Company Strategy and Development Direction - The company is focused on long-term growth driven by macro trends such as healthcare decentralization and the growth of generic medicines [6][7] - The company is ramping up share repurchases, having repurchased over $80 million worth of shares in the first quarter [13] - The company emphasizes sustainability as a competitive advantage, having received multiple awards for its efforts [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in growth prospects despite current economic uncertainties, highlighting resilience in essential product markets [28][30] - The company anticipates a strong second quarter with positive contributions from all segments, particularly in Pharma and Beauty [30][31] - Management acknowledged the evolving tariff situation but expects limited net effects on operations [25][82] Other Important Information - The effective tax rate for the first quarter was 25.8%, reflecting a temporary surtax enacted in France [15] - Free cash flow for the quarter was $26 million, with a strong balance sheet showing a cash balance of $126 million [23][24] Q&A Session Summary Question: Insights on order patterns and inventory levels - Management noted a reacceleration in orders across various segments, with U.S. inventories normalizing but not yet seen in other regions [35][37] Question: Impact of GLP-1s on injectables - Strong demand for GLP-1s is noted, with the company ramping up capabilities to meet this demand [36] Question: Tax rate guidance for the second half of the year - The expected effective tax rate for the second half is projected to be in the range of 22% to 24% [43] Question: Inventory status in cold and cough products - Management indicated that the U.S. has seen some inventory normalization, while other regions have not yet experienced this [48][49] Question: Outlook for tooling activity - Management expressed optimism about tooling activity, indicating it is on the rise as customers seek to differentiate their products [105]